| # | Title | Journal | Year | Citations |
|---|
| 1 | Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis | Journal of Hepatology | 2017 | 734 |
| 2 | Fecal Microbiome and Volatile Organic Compound Metabolome in Obese Humans With Nonalcoholic Fatty Liver Disease | Clinical Gastroenterology and Hepatology | 2013 | 564 |
| 3 | Crohn’s disease | Nature Reviews Disease Primers | 2020 | 420 |
| 4 | Association of host genome with intestinal microbial composition in a large healthy cohort | Nature Genetics | 2016 | 388 |
| 5 | The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm | Journal of Viral Hepatitis | 2014 | 372 |
| 6 | Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial | Lancet, The | 2015 | 354 |
| 7 | Clinical Practice Guidelines for the Use of Video Capsule Endoscopy | Gastroenterology | 2017 | 306 |
| 8 | Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography | Liver International | 2012 | 283 |
| 9 | Inclusion of Sarcopenia Within MELD (MELD-Sarcopenia) and the Prediction of Mortality in Patients With Cirrhosis | Clinical and Translational Gastroenterology | 2015 | 261 |
| 10 | The human gut microbiome: current knowledge, challenges, and future directions | Translational Research | 2012 | 249 |
| 11 | Mesenchymal Stromal/Stem Cells in Regenerative Medicine and Tissue Engineering | Stem Cells International | 2018 | 244 |
| 12 | Historical epidemiology of hepatitis C virus (HCV) in selected countries | Journal of Viral Hepatitis | 2014 | 211 |
| 13 | Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials | Lancet, The | 2022 | 187 |
| 14 | Strategies to manage hepatitis C virus (HCV) disease burden | Journal of Viral Hepatitis | 2014 | 161 |
| 15 | Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants | Human Molecular Genetics | 2012 | 139 |
| 16 | Rituximab for the Treatment of Patients with Autoimmune Hepatitis Who are Refractory or Intolerant to Standard Therapy | Canadian Journal of Gastroenterology & Hepatology | 2013 | 139 |
| 17 | Burden of Disease and Cost of Chronic Hepatitis C Virus Infection in Canada | Canadian Journal of Gastroenterology and Hepatology | 2014 | 131 |
| 18 | Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review | Clinical Gastroenterology and Hepatology | 2020 | 129 |
| 19 | Discordance in fibrosis staging between liver biopsy and transient elastography using the FibroScan XL probe | Journal of Hepatology | 2012 | 126 |
| 20 | Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases | Journal of Crohn's and Colitis | 2016 | 115 |
| 21 | Modern management of perianal fistulas in Crohn’s disease: future directions | Gut | 2018 | 114 |
| 22 | Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis | The Lancet Gastroenterology and Hepatology | 2021 | 114 |
| 23 | B-Cell Depletion With Rituximab in Patients With Primary Biliary Cirrhosis Refractory to Ursodeoxycholic Acid | American Journal of Gastroenterology | 2013 | 102 |
| 24 | An Update on the Management of Chronic Hepatitis C: Consensus Guidelines from the Canadian Association for the Study of the Liver | Canadian Journal of Gastroenterology & Hepatology | 2012 | 101 |
| 25 | Liver Stiffness by Transient Elastography Predicts Liver-Related Complications and Mortality in Patients with Chronic Liver Disease | PLoS ONE | 2014 | 98 |
| 26 | Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial | Lancet, The | 2022 | 94 |
| 27 | New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection | Gastroenterology | 2019 | 89 |
| 28 | Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial | European Journal of Nutrition | 2019 | 88 |
| 29 | Expert Consensus on Optimal Acquisition and Development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: A Reliability and Inter-rater Variability Study on Intestinal Ultrasonography in Crohn’s Disease | Journal of Crohn's and Colitis | 2021 | 83 |
| 30 | Consensus Statements From a Multidisciplinary Expert Panel on the Utilization and Application of a Liver-Specific MRI Contrast Agent (Gadoxetic Acid) | American Journal of Roentgenology | 2015 | 76 |
| 31 | Changes in Gastroenterology and Endoscopy Practices in Response to the Coronavirus Disease 2019 Pandemic: Results From a North American Survey | Gastroenterology | 2020 | 75 |
| 32 | An Update on the Management of Chronic Hepatitis C: 2015 Consensus Guidelines from the Canadian Association for the Study of the Liver | Canadian Journal of Gastroenterology and Hepatology | 2015 | 67 |
| 33 | Systematic review with meta‐analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease | Alimentary Pharmacology and Therapeutics | 2019 | 66 |
| 34 | Strategies for Detecting Colorectal Cancer in Patients with Inflammatory Bowel Disease: A Cochrane Systematic Review and Meta-Analysis | American Journal of Gastroenterology | 2018 | 65 |
| 35 | Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol | BMC Gastroenterology | 2015 | 59 |
| 36 | Embolization of portosystemic shunts for treatment of medically refractory hepatic encephalopathy | Liver Transplantation | 2016 | 59 |
| 37 | An intact microbiota is required for the gastrointestinal toxicity of the immunosuppressant mycophenolate mofetil | Journal of Heart and Lung Transplantation | 2018 | 59 |
| 38 | Fatigue in chronic liver disease: New insights and therapeutic approaches | Liver International | 2019 | 59 |
| 39 | The Clinical Implications of Nocebo Effects for Biosimilar Therapy | Frontiers in Pharmacology | 2019 | 59 |
| 40 | Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease | BioDrugs | 2020 | 58 |
| 41 | Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial | Human Vaccines and Immunotherapeutics | 2020 | 56 |
| 42 | An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: The Liver-FibroSTARD standards | Journal of Hepatology | 2015 | 54 |
| 43 | Systematic review of nutrition screening and assessment in inflammatory bowel disease | World Journal of Gastroenterology | 2019 | 54 |
| 44 | Morbidity and Mortality After Surgery for Nonmalignant Colorectal Polyps: A 10-Year Nationwide Analysis | American Journal of Gastroenterology | 2019 | 54 |
| 45 | The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long‐term nucleos(t)ide analogue therapy | Alimentary Pharmacology and Therapeutics | 2014 | 53 |
| 46 | Clinical course of 161 untreated and tenofovir‐treated chronic hepatitis B pregnant patients in a low hepatitis B virus endemic region | Journal of Viral Hepatitis | 2016 | 51 |
| 47 | Innovations in Oral Therapies for Inflammatory Bowel Disease | Drugs | 2019 | 51 |
| 48 | Defining Quality Indicators for Best-Practice Management of Inflammatory Bowel Disease in Canada | Canadian Journal of Gastroenterology and Hepatology | 2014 | 50 |
| 49 | The Feasibility and Reliability of Transient Elastography Using Fibroscan®: A Practice Audit of 2335 Examinations | Canadian Journal of Gastroenterology and Hepatology | 2014 | 48 |
| 50 | Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group | JHEP Reports | 2019 | 48 |
